VEWD
14.10.2021 14:50:07 CEST | Business Wire | Press release
Vewd , the leading provider of OTT software solutions, together with Vestel, Europe’s largest TV manufacturer, today introduced the Vewd Operator TV, a fully-featured Smart TV with a built-in, content-enriched Pay TV experience. Now, Pay TV Operators can win the retail Smart TV landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005674/en/
Rather than up-selling Pay TV services through a separate set-top box or competing alongside other apps inside hard-to-discover Smart TV app environments, operators can now own the entire Smart TV consumer experience – from home screen to app discoverability – from the moment a consumer purchases the TV.
Operator TV combines Vewd’s industry-leading Smart TV software with Vestel’s TV manufacturing, warehousing and distribution expertise. Vestel produces TV’s for more than 100 of the world’s iconic brands, including JVC, Hitachi, Telefunken, and Toshiba. Operators not only benefit from having a leading manufacturer for their own or co-branded televisions, but also can rely upon Vestel’s robust logistics capabilities to ensure simplified procurement, warehousing and delivery of their Operator TV.
“Vestel is pleased to add our expertise in building high-quality, full-featured Smart TVs to empower Vewd’s Operator TV solution,” said Barış Altınkaya, Vestel Vice President of Marketing and Product Management. “By working directly with Vewd and the Operator, we can leverage our vast manufacturing and retail distribution experience to contribute in reducing time-to-market, enabling substantial Operator CapEx savings while delivering an experience that delights subscribers, reduces churn and improves subscriber satisfaction.”
Vewd’s Software-as-a-Service (SaaS) business model aligns Operator TV with Pay TV subscription models and revenue, distributing costs, development time and risk. Critical functionality comes standard in an Operator TV:
- Conditional Access available to ensure broadcast and IP content security
- Cloud-managed reference user experience (UX) or the Operator’s customized UI
- Content including premium OTT and video-on-demand, FAST channels and full support for broadcast channels
“Operators have tried different strategies to embrace Smart TV, but together with Vestel, we've made the first solution that seamlessly connects Pay TV and Smart TV,” said Aneesh Rajaram, CEO of Vewd. “Consumers are streaming more and connecting fewer devices to the TV. As a result, Operators are forced to fight for visibility among Smart TV apps. Vewd Operator TV ensures Operators of any size can seize control from the start and win the home’s most important screen.”
Vewd's Operator TV solution is enabled via Vewd’s white-labeled product suite which includes Vewd OS . Visit our website to learn more about the benefits of Operator TV .
About Vewd
Vewd is the leading provider of OTT and hybrid TV solutions, connecting consumers anywhere to the content they love. By making OTT possible on almost 40 million connected devices each year, Vewd leads the way in defining the future of entertainment. Our suite of products and services are crafted to simplify complexity and offer solutions that unite the entire value chain, from silicon vendors to end-users. Market leaders such as Sony, Hisense, TPV, Vodafone, Sagemcom, and many more rely on Vewd products and services. Follow us, as we make TV connected. Visit Vewd.com to learn more.
About Vestel
Comprised of 28 companies, Vestel Group is a multi-industry manufacturer that operates in consumer electronics, home appliances, professional displays, LED lighting, and EV Chargers. Testimony to the global importance of Zorlu Holding across multiple technology sectors, Vestel is not only thriving at home in Turkey, but also through a further 10 subsidiaries that have been set up in various other parts of the world. Thanks to its renowned manufacturing and R&D complex, Vestel exports to 157 countries and keeps its position as a global player. More information: vestelinternational.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005674/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom